Clinical Phase I Trial of Cancer-Killing Virus G207 for the Treatment of Malignant Glioma Started
The trial will evaluate safety, tolerability and efficacy trends of G207 as well as potential synergies with radiation therapy. It is planned to enroll approximately 20 patients over the next 24 months. The study's principal investigator, James M. Markert, M.D., explains: "Previous clinical studies have shown that single doses of G207 administered intra-cerebrally are well tolerated and suggest that G207 may induce tumor regression. In addition, pre-clinical studies indicate synergism between G207 and radiation therapy."
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.